Back to Journals » Journal of Blood Medicine » Volume 5

A novel supplemental approach to capturing post-marketing safety information on recombinant factor VIIa in acquired hemophilia: the Acquired Hemophilia Surveillance project

Authors Lentz S, Tandra A, Gut R, Cooper DL

Received 1 October 2013

Accepted for publication 29 October 2013

Published 13 January 2014 Volume 2014:5 Pages 1—3


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Steven R Lentz,1 Anand Tandra,2 Robert Z Gut,3 David L Cooper3

1Division of Hematology, Oncology and Blood and Marrow Transplantation, Department of Internal Medicine, University of Iowa, Iowa City, IA, USA; 2Hematology, Indiana Hemophilia and Thrombosis Center, Indianapolis, IN, USA; 3Clinical, Medical, and Regulatory Affairs, Novo Nordisk, Inc, Princeton, NJ, USA

Acquired hemophilia (AH) is a rare (incidence is 1 per 1.5 million) but often severe bleeding disorder characterized by autoantibodies to coagulation factor VIII (FVIII). It is associated with life-threatening bleeding and ∼20% mortality.1,2 Recombinant factor VIIa (rFVIIa; NovoSeven® RT, Novo Nordisk A/S, Bagsværd, Denmark) received an indication from the US Food and Drug Administration (FDA) in October 2006 for the treatment of bleeding episodes and the prevention of bleeding in surgical interventions or invasive procedures in patients with AH.3

View original paper by Collins and colleagues.

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]